Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96EB1
UPID:
ELP4_HUMAN
Alternative names:
PAX6 neighbor gene protein
Alternative UPACC:
Q96EB1; B4E3W0; E7EPZ6; Q9H4E8; Q9NX11
Background:
Elongator complex protein 4, also known as PAX6 neighbor gene protein, plays a crucial role in the modification of tRNAs, facilitating the formation of carboxymethyluridine at the wobble base position 34. This process is essential for the accurate translation of genetic information into proteins.
Therapeutic significance:
The protein is implicated in Aniridia 2, a congenital disorder affecting eye development. A mutation affecting its regulatory element disrupts PAX6 expression, leading to iris hypoplasia and other ocular abnormalities. Understanding the role of Elongator complex protein 4 could open doors to potential therapeutic strategies for Aniridia 2 and related ocular conditions.